Swiss-Based Hedera Dx Raises €15M To Offer Better Cancer Tests And Treatments Globally

The round was led by Vsquared Ventures, with new investor Tesi joining, and ongoing support from Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.

Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, says, “Hedera Dx is addressing a critical gap in global oncology care. Hedera’s approach tackles the specific challenges of hospital in-house testing and results in more patients getting tested and more patients having access to targeted therapies.”

Dr. Rechsteiner adds, “Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within healthcare systems outside the US.”

The funding will help Hedera Dx improve access to targeted cancer treatments by removing key barriers. The company’s founders have experience leading and growing companies like Blueprint Genetics, Roche, and Molecular Health.

Read More - Way Data Technologies Funding News- Way Data Technologies Secures €2.6M In Pre-Seed Round

Hedera Dx has created blood-based cancer tests, called liquid biopsies, for hospital labs in areas without centralised testing. These tests are already being used in 11 European countries.

The company’s team of 20+ experts includes specialists in genomics, cancer care, AI, and digital health. Their platform also uses real-world data to help improve and develop cancer treatments.

Tommi Lehtonen, CEO and co-founder of Hedera Dx, says, “At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician globally. While there is a large number of personalised cancer treatments on the market, a very large part of patients still can’t access them. Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost-efficiently.”

“We’re not only improving access to advanced cancer care for patients — we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fueling the next wave of innovative cancer therapies,” adds Dr. Christian Meisel, CMO and co-founder of Hedera Dx.

Vsquared Ventures backs founders building deeptech solutions for big global challenges. Its focus areas include space, energy, computing, robotics, AI, software, and tech-bio. Portfolio companies include Isar Aerospace, IQM Quantum Computing, and Zama.ai.

Tesi (Finnish Industry Investment Ltd) is a state-owned investor that works on a market-driven model. It invests in VC and private equity funds, as well as directly in Finnish startups, growth companies, and large-scale industrial projects.

About Hedera Dx

Founded in 2021, Hedera Dx is making cancer care more precise and accessible. Its platform brings together advanced lab testing and clinical data to help doctors choose better treatments and support the development of new cancer drugs.